[go: up one dir, main page]

SI3666771T1 - LPA antagonisti - Google Patents

LPA antagonisti

Info

Publication number
SI3666771T1
SI3666771T1 SI201730979T SI201730979T SI3666771T1 SI 3666771 T1 SI3666771 T1 SI 3666771T1 SI 201730979 T SI201730979 T SI 201730979T SI 201730979 T SI201730979 T SI 201730979T SI 3666771 T1 SI3666771 T1 SI 3666771T1
Authority
SI
Slovenia
Prior art keywords
lpa antagonists
lpa
antagonists
Prior art date
Application number
SI201730979T
Other languages
English (en)
Inventor
Peter Tai Wah Cheng
Robert F. Kaltenbach Iii
Jun Li
Jun Shi
Yan Shi
Shiwei Tao
Hao Zhang
Suresh Dhanusu
Kumaravel Selvakumar
Ramesh Babu Reddigunta
Steven J. Walker
Lawrence J. Kennedy
James R. Corte
Tianan Fang
Sutjano Jusuf
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3666771T1 publication Critical patent/SI3666771T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
    • C07C62/10—Saturated compounds containing ether groups, groups, groups, or groups with a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
SI201730979T 2016-06-21 2017-06-20 LPA antagonisti SI3666771T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352792P 2016-06-21 2016-06-21
EP20154651.2A EP3666771B1 (en) 2016-06-21 2017-06-20 Lpa antagonists

Publications (1)

Publication Number Publication Date
SI3666771T1 true SI3666771T1 (sl) 2021-12-31

Family

ID=59258388

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201730979T SI3666771T1 (sl) 2016-06-21 2017-06-20 LPA antagonisti
SI201730240T SI3472148T1 (sl) 2016-06-21 2017-06-20 Karbamoiloksimetil triazol ciloheksilne kisline kot LPA antagonisti

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201730240T SI3472148T1 (sl) 2016-06-21 2017-06-20 Karbamoiloksimetil triazol ciloheksilne kisline kot LPA antagonisti

Country Status (32)

Country Link
US (8) US10071078B2 (sl)
EP (2) EP3666771B1 (sl)
JP (2) JP7073281B2 (sl)
KR (2) KR102463621B1 (sl)
CN (2) CN114601830A (sl)
AR (1) AR108838A1 (sl)
AU (2) AU2017281439B2 (sl)
CA (1) CA3029202C (sl)
CL (1) CL2018003708A1 (sl)
CO (1) CO2019000471A2 (sl)
CY (2) CY1123443T1 (sl)
DK (2) DK3666771T3 (sl)
EA (1) EA037585B1 (sl)
ES (2) ES2895385T3 (sl)
HR (2) HRP20200586T1 (sl)
HU (2) HUE057211T2 (sl)
IL (1) IL263767B (sl)
LT (2) LT3666771T (sl)
ME (1) ME03804B (sl)
MX (1) MX381205B (sl)
MY (1) MY195782A (sl)
PE (1) PE20190211A1 (sl)
PL (2) PL3666771T3 (sl)
PT (2) PT3666771T (sl)
RS (2) RS60347B1 (sl)
SG (1) SG11201811321TA (sl)
SI (2) SI3666771T1 (sl)
SM (2) SMT202000274T1 (sl)
TW (2) TWI757128B (sl)
UY (1) UY37302A (sl)
WO (1) WO2017223016A1 (sl)
ZA (1) ZA201808580B (sl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
US11319315B2 (en) * 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
EP3728222B1 (en) 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
WO2019126098A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126103A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
RS62710B1 (sr) 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
JP7301839B2 (ja) * 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸
EP3728242B1 (en) 2017-12-19 2023-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
ES2936517T3 (es) * 2017-12-19 2023-03-17 Bristol Myers Squibb Co Triazol azinas de ácido ciclohexílico como antagonistas de LPA
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
CN112702998A (zh) * 2018-09-18 2021-04-23 百时美施贵宝公司 作为lpa拮抗剂的环庚酸
JP7412424B2 (ja) * 2018-09-18 2024-01-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのオキサビシクロ酸
CN113473985A (zh) 2018-09-18 2021-10-01 百时美施贵宝公司 作为lpa拮抗剂的环戊酸
US20210379210A1 (en) * 2018-10-15 2021-12-09 Bristol-Myers Squibb Company Radioligands for imaging the lpa1 receptor
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
MX2021012357A (es) * 2019-04-16 2021-11-04 Bristol Myers Squibb Co Proceso para preparar compuestos de acido carbamoiloximetil triazol ciclohexilico.
EP3986551B1 (en) 2019-06-18 2025-10-29 Bristol-Myers Squibb Company Triazole carboxylic acids as lpa antagonists
CN114599641A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的环丁基羧酸
EP3986552B1 (en) * 2019-06-18 2024-09-18 Bristol-Myers Squibb Company Isoxazole carboxylic acids as lpa antagonists
CN119823001A (zh) 2019-07-30 2025-04-15 大正制药株式会社 拮抗lpa1受体的脲化合物
EP4058144A1 (en) * 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TW202134213A (zh) * 2019-11-29 2021-09-16 日商小野藥品工業股份有限公司 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
CN114746425A (zh) 2019-12-12 2022-07-12 奇斯药制品公司 作为lpa受体2抑制剂的噻吩并嘧啶衍生物
JP2023505703A (ja) 2019-12-12 2023-02-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｌｐａ受容体２阻害剤としての芳香族アミド誘導体
EP4072670B1 (en) 2019-12-12 2023-11-22 Chiesi Farmaceutici S.p.A. Quinazoline derivatives as lpa receptor 2 inhibitors
CN111195254B (zh) * 2020-02-25 2021-03-16 中国医学科学院阜外医院 Lpa2及其激动剂的应用
KR102393079B1 (ko) 2020-02-28 2022-04-29 한국화학연구원 가축 호흡기 질환의 예방 또는 치료용 조성물
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
JP2023533851A (ja) 2020-07-16 2023-08-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｌｐａ受容体阻害剤としてのアミドシクロヘキサン酸誘導体
CN116583501A (zh) * 2020-10-22 2023-08-11 罗特斯生物公司 用于治疗与lpa受体活性相关的病症的化合物和组合物
WO2022100623A1 (zh) * 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代杂环噻吩类化合物及其用途
CN114456147B (zh) * 2020-11-10 2025-07-15 武汉人福创新药物研发中心有限公司 氧取代氨基碳酸酯噻吩类化合物
WO2022100625A1 (zh) * 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
CN114621135B (zh) * 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
CN112778187B (zh) * 2021-01-06 2022-10-28 烟台舜康生物科技有限公司 一种海那替尼中间体的合成方法及所得的海纳替尼中间体
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
US20240190860A1 (en) 2021-03-24 2024-06-13 Chiesi Farmaceutici S.P.A. 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
JPWO2022270621A1 (sl) * 2021-06-25 2022-12-29
CN117460721A (zh) * 2021-07-20 2024-01-26 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
JP2024540937A (ja) * 2021-10-21 2024-11-06 ローツェ・バイオ・インコーポレイテッド Ｌｐａ受容体活性に関連する状態を処置するための化合物および組成物
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2023109878A1 (zh) * 2021-12-15 2023-06-22 武汉人福创新药物研发中心有限公司 三氮唑类lpar1拮抗剂及其用途
WO2023118253A1 (en) 2021-12-23 2023-06-29 Chiesi Farmaceutici S.P.A. Cyclohexane acid derivatives as lpa receptor inhibitors
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
EP4490150A1 (en) 2022-03-08 2025-01-15 Chiesi Farmaceutici S.p.A. Amido cyclopropyl derivatives as lpa receptor inhibitors
EP4493533A1 (en) 2022-03-15 2025-01-22 Bristol-Myers Squibb Company Biocatalytic synthesis of (1s,3s)-3-hydroxycyclohexane-1-carboxylic acid compounds
AU2023410884A1 (en) 2022-12-23 2025-08-07 Bristol-Myers Squibb Company Lpa1 antagonists for treating interstitial lung disease
TW202440089A (zh) 2022-12-23 2024-10-16 美商必治妥美雅史谷比公司 用於治療間質性肺病之lpa1拮抗劑
KR20250120434A (ko) 2022-12-23 2025-08-08 브리스톨-마이어스 스큅 컴퍼니 Lpa1 길항제의 결정질 형태
KR20250120435A (ko) 2022-12-23 2025-08-08 브리스톨-마이어스 스큅 컴퍼니 간질성 폐 질환을 치료하기 위한 lpa1 길항제
TW202432092A (zh) 2023-01-19 2024-08-16 大陸商江蘇恒瑞醫藥股份有限公司 三氮唑類化合物的可藥用鹽、晶型及其製備方法
WO2025051266A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途
WO2025051267A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途
CN117024409A (zh) * 2023-10-10 2023-11-10 药康众拓(北京)医药科技有限公司 氘代lpa1抑制剂化合物及其用途
WO2025162421A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 Lpar1拮抗剂及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1695422A (en) 1928-12-18 A cobpobation
US1695432A (en) 1924-03-18 1928-12-18 Arthur W Lovejoy Toilet-paper holder
US1695455A (en) 1925-12-07 1928-12-18 Delpech Jacques Apparatus for the manufacture of artificial filaments
US1677284A (en) 1926-04-23 1928-07-17 Goodrich Co B F Sheet material and method of making and mounting the same
US1695431A (en) 1926-10-05 1928-12-18 Fred H Linley Combustion control in steam-boiler furnaces
GB267434A (en) 1926-11-12 1927-03-17 Thomas Whyte Guthrie An improved billiard-cue tip
US1695454A (en) 1927-05-23 1928-12-18 Edward J Coyne Door spring
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
EA200601266A1 (ru) 2004-02-18 2007-02-27 Астразенека Аб Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
GB0806794D0 (en) 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
CN103189370B (zh) * 2010-11-09 2015-07-08 霍夫曼-拉罗奇有限公司 作为gaba受体用配体的三唑衍生物
AU2011338561A1 (en) 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
US8785442B2 (en) * 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
JP5976011B2 (ja) 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
WO2013085824A1 (en) * 2011-12-04 2013-06-13 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
WO2013189865A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
BR112014030685A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche compostos de n-alquiltriazol como antagonistas de lpar
WO2014001279A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AR108745A1 (es) 2016-06-21 2018-09-19 Syngenta Participations Ag Derivados de oxadiazol microbiocidas
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
JP7301839B2 (ja) 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
ES2936517T3 (es) 2017-12-19 2023-03-17 Bristol Myers Squibb Co Triazol azinas de ácido ciclohexílico como antagonistas de LPA
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
RS62710B1 (sr) 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
WO2019126098A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3728222B1 (en) 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
EP3728242B1 (en) 2017-12-19 2023-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists

Also Published As

Publication number Publication date
AU2017281439B2 (en) 2021-07-01
AU2021209334A1 (en) 2021-08-26
DK3472148T3 (da) 2020-04-27
EA037585B1 (ru) 2021-04-19
CO2019000471A2 (es) 2019-02-08
PT3666771T (pt) 2021-10-27
SI3472148T1 (sl) 2020-07-31
CL2018003708A1 (es) 2019-02-08
IL263767B (en) 2021-08-31
HRP20200586T1 (hr) 2020-07-10
MY195782A (en) 2023-02-13
WO2017223016A1 (en) 2017-12-28
AU2021209334B2 (en) 2023-06-01
HRP20211708T1 (hr) 2022-02-04
BR112018076558A2 (pt) 2019-04-02
PE20190211A1 (es) 2019-02-07
ES2785951T3 (es) 2020-10-08
US20250057815A1 (en) 2025-02-20
US20200138789A1 (en) 2020-05-07
US10071078B2 (en) 2018-09-11
HUE049944T2 (hu) 2020-11-30
USRE49352E1 (en) 2023-01-03
CA3029202C (en) 2022-03-01
US10576062B2 (en) 2020-03-03
US20220249443A1 (en) 2022-08-11
PL3472148T3 (pl) 2020-12-14
EP3472148B1 (en) 2020-03-11
EP3666771A1 (en) 2020-06-17
SG11201811321TA (en) 2019-01-30
AR108838A1 (es) 2018-10-03
PL3666771T3 (pl) 2021-12-27
RS60347B1 (sr) 2020-07-31
KR20190020049A (ko) 2019-02-27
LT3666771T (lt) 2021-12-10
CN114601830A (zh) 2022-06-10
TW202126629A (zh) 2021-07-16
HRP20211708T8 (hr) 2022-03-04
JP2022106974A (ja) 2022-07-20
US20180333395A1 (en) 2018-11-22
RS62524B1 (sr) 2021-11-30
CA3029202A1 (en) 2017-12-28
CN109963843B (zh) 2022-03-11
ES2895385T3 (es) 2022-02-21
EP3666771B1 (en) 2021-09-29
SMT202000274T1 (it) 2020-07-08
KR20220038537A (ko) 2022-03-28
US20230390249A1 (en) 2023-12-07
US20210244711A1 (en) 2021-08-12
KR102377340B1 (ko) 2022-03-21
CY1124737T1 (el) 2022-07-22
IL263767A (en) 2019-01-31
EA201892710A1 (ru) 2019-05-31
ZA201808580B (en) 2020-08-26
TWI757128B (zh) 2022-03-01
PT3472148T (pt) 2020-05-08
ME03804B (me) 2021-04-20
US20170360759A1 (en) 2017-12-21
JP7312295B2 (ja) 2023-07-20
CY1123443T1 (el) 2021-12-31
TW201808919A (zh) 2018-03-16
EP3472148A1 (en) 2019-04-24
TWI725200B (zh) 2021-04-21
CN109963843A (zh) 2019-07-02
DK3666771T3 (da) 2021-11-15
MX381205B (es) 2025-03-12
AU2017281439A1 (en) 2019-02-07
JP7073281B2 (ja) 2022-05-23
SMT202100614T1 (it) 2022-01-10
LT3472148T (lt) 2020-05-25
NZ750013A (en) 2022-03-25
MX2018015563A (es) 2019-06-06
JP2019518766A (ja) 2019-07-04
UY37302A (es) 2018-01-02
US11007180B2 (en) 2021-05-18
KR102463621B1 (ko) 2022-11-03
HUE057211T2 (hu) 2022-04-28

Similar Documents

Publication Publication Date Title
SMT202100614T1 (it) Antagonisti di lpa
DK3482386T3 (en) Patientsimulator
PL3445380T6 (pl) Bakterioterapia
DK3538786T3 (en) Friktionsmateriale
AU201710564S (en) Bookrack
GB201704891D0 (en) Environmetnal
GB201703126D0 (en) Stoßfãngermodul
GB201619778D0 (en) Polytunnel arrangement
GB201619993D0 (en) Flexi-bin
GB201614145D0 (en) FlashBet BetWheel
GB201817064D0 (en) Microtransporters
GB201602601D0 (en) Easybox2
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
GB201621210D0 (en) Polytunnel arrangement
AU2016360V (en) JCU7 Desmanthus leptophyllus
AU2016362V (en) JCU9 Desmanthus pernambucanus
GB201619489D0 (en) Biofumigant
GB201616396D0 (en) Coats2Pillow
GB201615484D0 (en) Disarmour
GB201614990D0 (en) Mozzipatch
GB201614694D0 (en) Hardwater
GB201613280D0 (en) Hardwater/electricty
HU4781U (hu) Külsõ tárolóhoz kapcsolt lemezelt autótakaró
GB201610014D0 (en) Polytunnel arrangement